<DOC>
	<DOCNO>NCT00003066</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness docetaxel combine estramustine treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Combined With Estramustine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , duration survival , quality life effect docetaxel estramustine combination woman metastatic breast cancer . OUTLINE : Patients receive estramustine 3 time day 3 day . Docetaxel begin day 3 a.m. dose estramustine give 1 hour infusion intravenously . Courses repeat every 21 day . If disease respond stable , treatment continue high tolerance percentage prescribe dose appearance disease progression . If complete response document , additional 2 course give . Patients receive minimum 2 course unless rapid progression unacceptable toxicity occur . Patients follow monthly . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Measurable evaluable disease Must ineligible high priority national institutional study No visible metastasis brain CT MRI ( unless single lesion amenable surgical resection ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : More 2 month Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 No prior clot disorder unless therapeutically anticoagulated Hepatic : Bilirubin le upper limit normal SGOT SGPT less 1.5 time normal Renal : BUN le 1.5 time normal Creatinine le 1.5 time normal Cardiovascular : No prior thromboembolism unless therapeutically anticoagulated Other : No symptomatic ascites , pleural effusion peripheral edema No serious medical psychiatric illness No prior malignancy curatively treat carcinoma situ cervix skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 2 week weekly regimen ) Any number prior chemotherapy regimen allow Endocrine therapy : Any number prior hormonal therapy regimens allow Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 1 week since prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>